Search Results - "Gershenwald, Jeffrey E"

Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond by Gershenwald, Jeffrey E., Scolyer, Richard A.

Get full text

The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care by Keung, Emily Z., Gershenwald, Jeffrey E.

“…Introduction: The eighth edition of the American Joint Committee on Cancer (AJCC) melanoma staging system was implemented in the United States on 1 January…”
Get full text

The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging by Amin, Mahul B., Greene, Frederick L., Edge, Stephen B., Compton, Carolyn C., Gershenwald, Jeffrey E., Brookland, Robert K., Meyer, Laura, Gress, Donna M., Byrd, David R., Winchester, David P.

“…The American Joint Committee on Cancer (AJCC) staging manual has become the benchmark for classifying patients with cancer, defining prognosis, and determining…”
Get full text

Guidelines of care for the management of primary cutaneous melanoma by Swetter, Susan M., Tsao, Hensin, Bichakjian, Christopher K., Curiel-Lewandrowski, Clara, Elder, David E., Gershenwald, Jeffrey E., Guild, Valerie, Grant-Kels, Jane M., Halpern, Allan C., Johnson, Timothy M., Sober, Arthur J., Thompson, John A., Wisco, Oliver J., Wyatt, Samantha, Hu, Shasa, Lamina, Toyin

“…The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer–related deaths, but treatment is…”
Get full text

NRAS mutation status is an independent prognostic factor in metastatic melanoma by Jakob, John A., Bassett, Roland L., Ng, Chaan S., Curry, Jonathan L., Joseph, Richard W., Alvarado, Gladys C., Rohlfs, Michelle L., Richard, Jessie, Gershenwald, Jeffrey E., Kim, Kevin B., Lazar, Alexander J., Hwu, Patrick, Davies, Michael A.

“…BACKGROUND: There is a need for improved prognostic markers in melanoma. In this study, the authors tested the prognostic significance and clinicopathologic…”
Get full text

A Landscape of Driver Mutations in Melanoma by Hodis, Eran, Watson, Ian R., Kryukov, Gregory V., Arold, Stefan T., Imielinski, Marcin, Theurillat, Jean-Philippe, Nickerson, Elizabeth, Auclair, Daniel, Li, Liren, Place, Chelsea, DiCara, Daniel, Ramos, Alex H., Lawrence, Michael S., Cibulskis, Kristian, Sivachenko, Andrey, Voet, Douglas, Saksena, Gordon, Stransky, Nicolas, Onofrio, Robert C., Winckler, Wendy, Ardlie, Kristin, Wagle, Nikhil, Wargo, Jennifer, Chong, Kelly, Morton, Donald L., Stemke-Hale, Katherine, Chen, Guo, Noble, Michael, Meyerson, Matthew, Ladbury, John E., Davies, Michael A., Gershenwald, Jeffrey E., Wagner, Stephan N., Hoon, Dave S.B., Schadendorf, Dirk, Lander, Eric S., Gabriel, Stacey B., Getz, Gad, Garraway, Levi A., Chin, Lynda

“…Despite recent insights into melanoma genetics, systematic surveys for driver mutations are challenged by an abundance of passenger mutations caused by…”
Get full text

American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine by Kattan, Michael W., Hess, Kenneth R., Amin, Mahul B., Lu, Ying, Moons, Karl G.M., Gershenwald, Jeffrey E., Gimotty, Phyllis A., Guinney, Justin H., Halabi, Susan, Lazar, Alexander J., Mahar, Alyson L., Patel, Tushar, Sargent, Daniel J., Weiser, Martin R., Compton, Carolyn

“…The American Joint Committee on Cancer (AJCC) has increasingly recognized the need for more personalized probabilistic predictions than those delivered by…”
Get full text

Final Version of 2009 AJCC Melanoma Staging and Classification by Balch, Charles M, Gershenwald, Jeffrey E, Soong, Seng-Jaw, Thompson, John F, Atkins, Michael B, Byrd, David R, Buzaid, Antonio C, Cochran, Alistair J, Coit, Daniel G, Ding, Shouluan, Eggermont, Alexander M, Flaherty, Keith T, Gimotty, Phyllis A, Kirkwood, John M, McMasters, Kelly M, Mihm, Jr, Martin C, Morton, Donald L, Ross, Merrick I, Sober, Arthur J, Sondak, Vernon K

“…To revise the staging system for cutaneous melanoma on the basis of data from an expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database…”
Get full text

FOXD3 Regulates VISTA Expression in Melanoma by Rosenbaum, Sheera R., Knecht, Meghan, Mollaee, Mehri, Zhong, Zhijiu, Erkes, Dan A., McCue, Peter A., Chervoneva, Inna, Berger, Adam C., Lo, Jennifer A., Fisher, David E., Gershenwald, Jeffrey E., Davies, Michael A., Purwin, Timothy J., Aplin, Andrew E.

“…Immune checkpoint inhibitors have improved patient survival in melanoma, but the innate resistance of many patients necessitates the investigation of…”
Get full text

Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases by BALCH, Charles M, GERSHENWALD, Jeffrey E, JOHNSON, Timothy, KIRKWOOD, John M, LEONG, Stanley P, MCMASTERS, Kelly M, MIHM, Martin C, MORTON, Donald L, ROSS, Merrick I, SONDAK, Vernon K, SOONG, Seng-Jaw, THOMPSON, John F, SHOULUAN DING, BYRD, David R, CASCINELLI, Natale, COCHRAN, Alistair J, COIT, Daniel G, EGGERMONT, Alexander M

“…To determine the survival rates and independent predictors of survival using a contemporary international cohort of patients with stage III melanoma. Complete…”
Get full text

Circulating Tumor Cells and Early Relapse in Node-positive Melanoma by Lucci, Anthony, Hall, Carolyn S, Patel, Sapna P, Narendran, Boomadevi, Bauldry, Jessica B, Royal, Richard E, Karhade, Mandar, Upshaw, Joshua R, Wargo, Jennifer A, Glitza, Isabella C, Wong, Michael K K, Amaria, Rodabe N, Tawbi, Hussein A, Diab, Adi, Davies, Michael A, Gershenwald, Jeffrey E, Lee, Jeffrey E, Hwu, Patrick, Ross, Merrick I

“…There is a need for sensitive, reproducible biomarkers for patients with stage III melanoma to guide clinical decision making. Circulating tumor cells (CTCs)…”
Get full text

Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system by Lemos, Bianca D., MD, Storer, Barry E., PhD, Iyer, Jayasri G., MD, Phillips, Jerri Linn, MA, CTR, Bichakjian, Christopher K., MD, Fang, L. Christine, MD, Johnson, Timothy M., MD, Liegeois-Kwon, Nanette J., MD, PhD, Otley, Clark C., MD, Paulson, Kelly G., PhD, Ross, Merrick I., MD, Yu, Siegrid S., MD, Zeitouni, Nathalie C., MD, Byrd, David R., MD, Sondak, Vernon K., MD, Gershenwald, Jeffrey E., MD, Sober, Arthur J., MD, Nghiem, Paul, MD, PhD

“…Background The management of Merkel cell carcinoma (MCC) has been complicated by a lack of detailed prognostic data and by the presence of conflicting staging…”
Get full text

Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database by THOMPSON, John F, SOONG, Seng-Jaw, LEONG, Stanley P, ROSS, Merrick I, BYRD, David R, CASCINELLI, Natale, COCHRAN, Alistair J, EGGERMONT, Alexander M, MCMASTERS, Kelly M, MIHM, Martin C, MORTON, Donald L, SONDAK, Vernon K, BALCH, Charles M, GERSHENWALD, Jeffrey E, SHOULUAN DING, COIT, Daniel G, FLAHERTY, Keith T, GIMOTTY, Phyllis A, JOHNSON, Timothy, JOHNSON, Marcella M

“…The aim of this study was to assess the independent prognostic value of primary tumor mitotic rate compared with other clinical and pathologic features of…”
Get full text

Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma by ELLERHORST, Julie A, GREENE, Victoria R, GRIMM, Elizabeth A, EKMEKCIOGLU, Suhendan, WARNEKE, Carla L, JOHNSON, Marcella M, COOKE, Carolyn P, WANG, Li-E, PRIETO, Victor G, GERSHENWALD, Jeffrey E, QINGYI WEI

“…NRAS and BRAF mutations are common in cutaneous melanomas, although rarely detected mutually in the same tumor. Distinct clinical correlates of these mutations…”
Get full text

Staging and Prognosis of Cutaneous Melanoma by Dickson, Paxton V., MD, Gershenwald, Jeffrey E., MD

“…Staging of cutaneous melanoma continues to evolve through identification and rigorous analysis of potential prognostic factors. In 1998, the American Joint…”
Get full text

High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens by Cheng, Lauren Y., Haydu, Lauren E., Song, Ping, Nie, Jianyi, Tetzlaff, Michael T., Kwong, Lawrence N., Gershenwald, Jeffrey E., Davies, Michael A., Zhang, David Yu

“…Mutations in the BRAF gene at or near the p. V600 locus are informative for therapy selection, but current methods for analyzing FFPE tissue DNA generally have…”
Get full text

The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022 by Ascierto, Paolo A, Blank, Christian, Eggermont, Alexander M, Garbe, Claus, Gershenwald, Jeffrey E, Hamid, Omid, Hauschild, Axel, Luke, Jason J, Mehnert, Janice M, Sosman, Jeffrey A, Tawbi, Hussein A, Mandalà, Mario, Testori, Alessandro, Caracò, Corrado, Osman, Iman, Puzanov, Igor

“…The Great Debate session at the 2022 Melanoma Bridge congress (December 1-3) featured counterpoint views from leading experts on five contemporary topics of…”
Get full text

Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma by Iyer, Jayasri G., MD, Storer, Barry E., PhD, Paulson, Kelly G., MD, PhD, Lemos, Bianca, MD, Phillips, Jerri Linn, MA, CTR, Bichakjian, Christopher K., MD, Zeitouni, Nathalie, MD, Gershenwald, Jeffrey E., MD, Sondak, Vernon, MD, Otley, Clark C., MD, Yu, Siegrid S., MD, Johnson, Timothy M., MD, Liegeois, Nanette J., MD, Byrd, David, MD, Sober, Arthur, MD, Nghiem, Paul, MD, PhD

“…Background The effects of primary tumor size on nodal involvement and of number of involved nodes on survival have not, to our knowledge, been examined in a…”
Get full text

Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma by DAVIES, Michael A, STEMKE-HALE, Katherine, PRIETO, Victor G, ALDAPE, Kenneth, MILLS, Gordon B, GERSHENWALD, Jeffrey E, LIN, E, TELLEZ, Carmen, WANLENG DENG, GOPAL, Yennu N, WOODMAN, Scott E, CALDERONE, Tiffany C, ZHENLIN JU, LAZAR, Alexander J

“…Purpose: Activation of the phosphoinositide 3-kinase (PI3K)-AKT pathway has been implicated in melanoma based primarily on the prevalence of mutations in PTEN…”
Get full text

Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes by Fang, Shenying, Wang, Yuling, Dang, Yifang, Gagel, Andrew, Ross, Merrick I., Gershenwald, Jeffrey E., Cormier, Janice N., Wargo, Jennifer, Haydu, Lauren E., Davies, Michael A., McQuade, Jennifer L., Sui, Dawen, Bassett, Roland L., Reveille, John D., Wei, Qingyi, Amos, Christopher I., Lee, Jeffrey E.

Get full text